BioSpace News Archive

Lannett Company, Inc. announced its participation at two upcoming investor conferences.

Alkermes plc announced the initiation of the monotherapy expansion stage of its ARTISTRY-1 clinical trial to evaluate the efficacy, safety and tolerability of ALKS 4230 in treating patients with renal cell carcinoma or melanoma.

Nonalcoholic Steatohepatitis will next year be the number one cause of liver transplants

Publication demonstrates specific U2AF1 splicing factor mutations induce oncogenic IRAK4-L isoform and activate innate immune pathways in myeloid malignancies

The Company Expects to Initiate a Phase 2 Trial in Patients with Schizophrenia in the Fourth Quarter of 2019

IMV Inc. (Nasdaq:IMV; TSX:IMV), a clinical stage immuno-oncology corporation, today announced updated data from the ongoing investigator-sponsored SPiReL Phase 2 clinical trial assessing IMV’s lead candidate, DPX-Survivac, in combination with intermittent low dose cyclophosphamide and Merck’s checkpoint inhibitor Keytruda® (pembrolizumab).

The acquisition means that the previously announced exclusive licence agreement with Novimmune will be superseded.

Following the announcement of the acquisition of emapalumab and related assets, Sobi™ intends to carry out a reorganisation to increase the focus of research & development resources to support its two core therapeutic areas: Haematology and Immunology.

Leading window and door brand puts sound performance on dynamic display with home activation showcasing noise-reducing window and patio door products Monday, June 17, 2019 from 4 p.m. to 7 p.m.

Genetic testing can identify causes of rare, progressive eye disorders